Abstract
Post-traumatic stress disorder (PTSD) is an anxiety disorder that develops after experiencing trauma. Actual therapies do not help majority of patients with PTSD. Moreover, extinguished fear memories usually reappear in the individuals when exposed to trauma cues. New drugs to reduce the impact of conditioned cues in eliciting abnormal fear responses are urgently required. Cotinine, the main metabolite of nicotine, decreased anxiety and depressive-like behavior, and enhanced fear extinction in mouse models of PTSD. Cotinine, considered a positive modulator of the α7 nicotinic acetylcholine receptor (α7nAChR), enhances fear extinction in rodents in a manner dependent on the activity of the αnAChRs. Cotinine stimulates signaling pathways downstream of α7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3β (GSK3β) pathway and the extracellular signal-regulated kinases (ERKs). The stimulation of these factors promotes synaptic plasticity and the extinction of fear. In this review, we discuss the hypothesis that cotinine relieves PTSD symptoms and facilitates fear memory extinction by promoting brain plasticity through the positive modulation of presynaptic nAChRs and its effectors in the brain.
Keywords: Anxiety, depressive-like behavior, fear extinction, tobacco, trauma.
Current Pharmaceutical Design
Title:Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Volume: 21 Issue: 25
Author(s): George E Barreto, Alexander Yarkov, Marcos Avila-Rodriguez, Gjumrakch Aliev and Valentina Echeverria
Affiliation:
Keywords: Anxiety, depressive-like behavior, fear extinction, tobacco, trauma.
Abstract: Post-traumatic stress disorder (PTSD) is an anxiety disorder that develops after experiencing trauma. Actual therapies do not help majority of patients with PTSD. Moreover, extinguished fear memories usually reappear in the individuals when exposed to trauma cues. New drugs to reduce the impact of conditioned cues in eliciting abnormal fear responses are urgently required. Cotinine, the main metabolite of nicotine, decreased anxiety and depressive-like behavior, and enhanced fear extinction in mouse models of PTSD. Cotinine, considered a positive modulator of the α7 nicotinic acetylcholine receptor (α7nAChR), enhances fear extinction in rodents in a manner dependent on the activity of the αnAChRs. Cotinine stimulates signaling pathways downstream of α7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3β (GSK3β) pathway and the extracellular signal-regulated kinases (ERKs). The stimulation of these factors promotes synaptic plasticity and the extinction of fear. In this review, we discuss the hypothesis that cotinine relieves PTSD symptoms and facilitates fear memory extinction by promoting brain plasticity through the positive modulation of presynaptic nAChRs and its effectors in the brain.
Export Options
About this article
Cite this article as:
Barreto E George, Yarkov Alexander, Avila-Rodriguez Marcos, Aliev Gjumrakch and Echeverria Valentina, Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder, Current Pharmaceutical Design 2015; 21 (25) . https://dx.doi.org/10.2174/1381612821666150710145250
DOI https://dx.doi.org/10.2174/1381612821666150710145250 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Breakfast and Learning: An Updated Review
Current Nutrition & Food Science Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Apoptosis in Drug Response
Current Pharmacogenomics Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Association Between Total Bilirubin Levels and Cardio-Metabolic Risk Factors Related to Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Gene Expression Signatures in Primary Immunodeficiencies: The Experience from Human Disease and Mouse Models
Current Molecular Medicine Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets